IP Library Granted Patent US 10,077,427
Granted Patent B2
US 10,077,427 · App. 14/669,916 · Granted Sep 18, 2018

Means and methods for influencing the stability of cells

Inventor: Hergen Spits (Amsterdam, NL)
Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM; AIMM THERAPEUTICS B.V.
C12N5/0635C07K16/00C12N2501/23C12N2501/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,077,427
App. No.
14/669,916
Granted
Sep 18, 2018
Kind
B2
Abstract

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Claims (7)

1. A composition comprising: an isolated antibody producing cell that is stable for at least nine weeks, comprising an exogenous nucleic acid sequence encoding BCL6 or a functional part thereof; and IL-21 and/or IL-10.

2. The composition of claim 1 , comprising IL-21.

3. The composition of claim 1 , comprising an exogenous nucleic acid sequence encoding constitutively active BCL6.

4. The composition of claim 1 , wherein said cell is a human cell producing human antibodies.

5. The composition of claim 1 , wherein the antibody producing cell produces an antibody of interest.

6. A composition comprising: an isolated antibody producing cell that is stable for at least nine weeks, comprising an exogenous nucleic acid sequence encoding BCL6 or a functional part thereof; and IL-21.

7. An isolated antibody producing cell that is stable for at least nine weeks, comprising (i) an exogenous nucleic acid sequence encoding BCL6 or a functional part thereof; and (ii) IL-21.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: AIMM THERAPEUTICS B.V.
To: KLING BIOTHERAPEUTICS B.V.
Reel/Frame 055711/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2015
From: SPITS, HERGEN
To: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM; AIMM THERAPEUTICS B.V.
Reel/Frame 036162/0682 →
Continuity (2)
Continuation 12086269
Related Publication 20150203816A1 · Jul 23, 2015